Top

Published in:

01-06-2015 | Review Article

The roles of AXIN2 in tumorigenesis and epigenetic regulation

Authors: Shuang Li, Chunpeng Wang, Xiaodong Liu, Shucheng Hua, Xin Liu

Published in: Familial Cancer | Issue 2/2015

Abstract

AXIN2, an important regulator in Wnt/β-catenin signaling pathway, takes part in regulating cell proliferation, cytometaplasia, migration, apoptosis and other important functions, has showed close relations with the development of liver cancer, colon cancer, lung cancer, breast cancer and so on. The epigenetic regulation provides new insights for further exploring the pathogenesis of tumor. In this paper, the roles of AXIN2 in tumorigenesis, AXIN2 methylation, ubiquitination and siRNA/RNA regulation will be reviewed.

Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL 3rd, Lee JJ, Tilghman SM, Gumbiner BM, Costantini F (1997) The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90(1):181–192CrossRefPubMed

Dong X, Seelan RS, Qian C, Mai M, Liu W (2001) Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene. Cytogenet Cell Genet 93(1–2):26–28. doi:10.1159/000056942 CrossRefPubMed

Mai M, Qian C, Yokomizo A, Smith DI, Liu W (1999) Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23–q24. Genomics 55(3):341–344. doi:10.1006/geno.1998.5650 CrossRefPubMed

Zeng YA, Nusse R (2010) Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 6(6):568–577. doi:10.1016/j.stem.2010.03.020 CrossRefPubMedCentralPubMed

Fancy SP, Harrington EP, Yuen TJ, Silbereis JC, Zhao C, Baranzini SE, Bruce CC, Otero JJ, Huang EJ, Nusse R, Franklin RJ, Rowitch DH (2011) Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci 14(8):1009–1016. doi:10.1038/nn.2855 CrossRefPubMedCentralPubMed

Kim JS, Park SY, Lee SA, Park MG, Yu SK, Lee MH, Park MR, Kim SG, Oh JS, Lee SY, Kim CS, Kim HJ, Chun HS, Moon SM, Kim DK (2014) MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. Mol Cell Biochem 387(1–2):71–79. doi:10.1007/s11010-013-1872-7 CrossRefPubMed

Ying Y, Tao Q (2009) Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 4(5):307–312CrossRefPubMed

Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, Liu PS, Bheddah S, Tao J, Lill JR, Hongo JA, Davis D, Kirkpatrick DS, Polakis P, Costa M (2011) Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One 6(7):e22595. doi:10.1371/journal.pone.0022595 CrossRefPubMedCentralPubMed

Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE (2013) The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer 13:174. doi:10.1186/1471-2407-13-174 CrossRefPubMedCentralPubMed

10.

Kikuchi A, Kishida S, Yamamoto H (2006) Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med 38(1):1–10. doi:10.1038/emm.2006.1 CrossRefPubMed

11.

Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205. doi:10.1016/j.cell.2012.05.012 CrossRefPubMed

12.

Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22(4):1172–1183CrossRefPubMedCentralPubMed

13.

Rennoll SA, Konsavage WM Jr, Yochum GS (2014) Nuclear AXIN2 represses MYC gene expression. Biochem Biophys Res Commun 443(1):217–222. doi:10.1016/j.bbrc.2013.11.089 CrossRefPubMedCentralPubMed

14.

Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, Pirinen S, Nieminen P (2004) Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74(5):1043–1050. doi:10.1086/386293 CrossRefPubMedCentralPubMed

15.

Rivera B, Perea J, Sanchez E, Villapun M, Sanchez-Tome E, Mercadillo F, Robledo M, Benitez J, Urioste M (2014) A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia. Eur J Hum Genet 22(3):423–426. doi:10.1038/ejhg.2013.146 CrossRefPubMedCentralPubMed

16.

Castiglia D, Bernardini S, Alvino E, Pagani E, De Luca N, Falcinelli S, Pacchiarotti A, Bonmassar E, Zambruno G, D’Atri S (2008) Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosom Cancer 47(7):614–624. doi:10.1002/gcc.20567 CrossRefPubMed

17.

Kim MS, Kim SS, Ahn CH, Yoo NJ, Lee SH (2009) Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability. Hum Pathol 40(1):58–64. doi:10.1016/j.humpath.2008.06.006 CrossRefPubMed

18.

Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO, Lothe RA (2005) Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 7(2):99–108. doi:10.1593/neo.04448 CrossRefPubMedCentralPubMed

19.

Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN (2000) Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 26(2):146–147. doi:10.1038/79859 CrossRefPubMed

20.

Marvin ML, Mazzoni SM, Herron CM, Edwards S, Gruber SB, Petty EM (2011) AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am J Med Genet A 155A(4):898–902. doi:10.1002/ajmg.a.33927 CrossRefPubMed

21.

Gong F, Miller KM (2013) Mammalian DNA repair: hATs and HDACs make their mark through histone acetylation. Mutat Res 750(1–2):23–30. doi:10.1016/j.mrfmmm.2013.07.002 CrossRefPubMed

22.

Lau PN, Cheung P (2011) Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing. Proc Natl Acad Sci USA 108(7):2801–2806. doi:10.1073/pnas.1012798108 CrossRefPubMedCentralPubMed

23.

Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693–705. doi:10.1016/j.cell.2007.02.005 CrossRefPubMed

24.

Balgkouranidou I, Liloglou T, Lianidou ES (2013) Lung cancer epigenetics: emerging biomarkers. Biomark Med 7(1):49–58. doi:10.2217/bmm.12.111 CrossRefPubMed

25.

Pontier DB, Gribnau J (2011) Xist regulation and function explored. Hum Genet 130(2):223–236. doi:10.1007/s00439-011-1008-7 CrossRefPubMedCentralPubMed

26.

Kerr KM, Galler JS, Hagen JA, Laird PW, Laird-Offringa IA (2007) The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers 23(1–2):5–30CrossRefPubMedCentralPubMed

27.

Jing F, Zhang J, Tao J, Zhou Y, Jun L, Tang X, Wang Y, Hai H (2007) Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie 30(1–2):14–19. doi:10.1159/000096892 CrossRefPubMed

28.

Mueller WC, von Deimling A (2009) Gene regulation by methylation. Recent Results Cancer Res 171:217–239. doi:10.1007/978-3-540-31206-2_13 CrossRefPubMed

29.

Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 349(21):2042–2054. doi:10.1056/NEJMra023075 CrossRefPubMed

30.

Figueroa ME, Chen SC, Andersson AK, Phillips LA, Li Y, Sotzen J, Kundu M, Downing JR, Melnick A, Mullighan CG (2013) Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Investig 123(7):3099–3111. doi:10.1172/JCI66203 CrossRefPubMedCentralPubMed

31.

Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6(8):597–610. doi:10.1038/nrg1655 CrossRefPubMed

32.

Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39(4):457–466. doi:10.1038/ng1990 CrossRefPubMed

33.

Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, Townsend CM Jr, Liu C, Evers BM (2013) Deregulation of Wnt/beta-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis 34(5):953–961. doi:10.1093/carcin/bgt018 CrossRefPubMedCentralPubMed

34.

Koinuma K, Yamashita Y, Liu W, Hatanaka H, Kurashina K, Wada T, Takada S, Kaneda R, Choi YL, Fujiwara SI, Miyakura Y, Nagai H, Mano H (2006) Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability. Oncogene 25(1):139–146. doi:10.1038/sj.onc.1209009 PubMed

35.

Naghibalhossaini F, Zamani M, Mokarram P, Khalili I, Rasti M, Mostafavi-Pour Z (2012) Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep 39(5):6171–6178. doi:10.1007/s11033-011-1434-6 CrossRefPubMed

36.

Tseng RC, Lin RK, Wen CK, Tseng C, Hsu HS, Hsu WH, Wang YC (2008) Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. Oncogene 27(32):4488–4496. doi:10.1038/onc.2008.83 CrossRefPubMed

37.

Ye Y, Rape M (2009) Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol 10(11):755–764. doi:10.1038/nrm2780 CrossRefPubMedCentralPubMed

38.

Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264):614–620. doi:10.1038/nature08356 CrossRefPubMed

39.

Bao R, Christova T, Song S, Angers S, Yan X, Attisano L (2012) Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One 7(11):e48670. doi:10.1371/journal.pone.0048670 CrossRefPubMedCentralPubMed

40.

Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs. Cell 136(4):629–641. doi:10.1016/j.cell.2009.02.006 CrossRefPubMed

41.

Zaratiegui M, Irvine DV, Martienssen RA (2007) Noncoding RNAs and gene silencing. Cell 128(4):763–776. doi:10.1016/j.cell.2007.02.016 CrossRefPubMed

42.

Bergmann C, Akhmetshina A, Dees C, Palumbo K, Zerr P, Beyer C, Zwerina J, Distler O, Schett G, Distler JH (2011) Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 70(12):2191–2198. doi:10.1136/ard.2010.147140 CrossRefPubMed

43.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297CrossRefPubMed

44.

Kim VN, Nam JW (2006) Genomics of microRNA. Trends Genet 22(3):165–173. doi:10.1016/j.tig.2006.01.003 CrossRefPubMed

45.

Li JH, Liu S, Zhou H, Qu LH, Yang JH (2014) starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 42(Database issue):D92–D97. doi:10.1093/nar/gkt1248 CrossRefPubMedCentralPubMed

46.

Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, Gerangelos S, Koziris N, Dalamagas T, Hatzigeorgiou AG (2012) TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res 40(Database issue):D222–D229. doi:10.1093/nar/gkr1161 CrossRefPubMedCentralPubMed

47.

Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, Lopez R (2010) A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res 38(Web Server issue):W695–W699. doi:10.1093/nar/gkq313 CrossRefPubMedCentralPubMed

48.

Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM, Athey BD (2009) New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res 19(7):1175–1183. doi:10.1101/gr.089367.108 CrossRefPubMedCentralPubMed

49.

Liu X, He M, Hou Y, Liang B, Zhao L, Ma S, Yu Y (2013) Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol Rep 29(4):1415–1420. doi:10.3892/or.2013.2263 PubMed

50.

Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, Rowe RG, Lee S, Maher CA, Weiss SJ, Yook JI (2011) A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. J cell biol 195(3):417–433. doi:10.1083/jcb.201103097 CrossRefPubMedCentralPubMed

51.

Wong KY, Yu L, Chim CS (2011) DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics 3(1):83–92. doi:10.2217/epi.10.74 CrossRefPubMed

52.

Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA (2011) EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 71(8):3087–3097. doi:10.1158/0008-5472.CAN-10-3035 CrossRefPubMedCentralPubMed

53.

Diaz-Martin J, Diaz-Lopez A, Moreno-Bueno G, Castilla MA, Rosa-Rosa JM, Cano A, Palacios J (2014) A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol 232(3):319–329. doi:10.1002/path.4289 CrossRefPubMed

54.

Lee JY, Park MK, Park JH, Lee HJ, Shin DH, Kang Y, Lee CH, Kong G (2014) Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 33(10):1325–1335. doi:10.1038/onc.2013.53 CrossRefPubMed

55.

Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ, Kench JG, Sutherland RL, Clark SJ (2013) Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 32(23):2891–2899. doi:10.1038/onc.2012.300 CrossRefPubMed

56.

Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1:e105. doi:10.1038/cddis.2010.85 CrossRefPubMedCentralPubMed

57.

Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, Hermeking H (2013) Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res 19(3):710–720. doi:10.1158/1078-0432.CCR-12-1703 CrossRefPubMed

58.

Roy S, Levi E, Majumdar AP, Sarkar FH (2012) Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol 5:58. doi:10.1186/1756-8722-5-58 CrossRefPubMedCentralPubMed

59.

Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7(16):2591–2600CrossRefPubMed

60.

Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF, Liang R (2010) Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31(4):745–750. doi:10.1093/carcin/bgq033 CrossRefPubMed

Title: The roles of AXIN2 in tumorigenesis and epigenetic regulation
Authors: Shuang Li
Chunpeng Wang
Xiaodong Liu
Shucheng Hua
Xin Liu
Publication date: 01-06-2015
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 2/2015
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-014-9775-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Mutations of HNRNPA0 and WIF1 predispose members of a large family to multiple cancers

Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome

A risk of digestive tract neoplasms susceptibility in miR-146a and miR-196a2

Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features

Health professionals’ evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer

The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer